Our Focus

Ultimate Medicine develops novel small molecules to improve cognitive function and treat dementia by targeting a unique gut-derived metabolite that increases with age and contributes to cognitive decline. Our approach offers a first-in-class mechanism to restore brain health by intervening at the gut-brain axis.

Our Impetus

The causative factors for cognitive impairment and dementia are complex interactions between genetics, environment, and whole-body physiology. While most therapies target the brain directly, growing evidence highlights the gut microbiome and its metabolic output as a critical and modifiable influence on cognitive health.

As the body ages, the molecular gut markers change and the integrity of the gut barrier weakens, leading to changes in the types and levels of microbial metabolites that enter circulation. These circulating metabolites can impact brain function by altering cellular energy production and neuronal signaling. In cognitive disorders, changes in systemic metabolite patterns are strongly correlated with disease progression, underscoring their value as both biomarkers and treatment targets.

Ultimate Medicine is developing small molecule therapies that modulate this gut-derived metabolic activity which offers a novel, systemic route to preserve cognitive function, support brain resilience, and extend quality of life.

About Us

Ultimate Medicine AG is a Swiss preclinical pharmaceutical company pioneering an innovative oral treatment for age-related cognitive disorders, including Alzheimer's disease. Our approach uniquely targets a key disease pathway that current therapies have overlooked, complementing existing research on amyloid-β and tau. With decades of pharmaceutical development and commercialization experience, our team is dedicated to developing a treatment that may potentially slow or halt cognitive decline. Supported by peer-reviewed research in Nature Aging, our companion diagnostic program is designed to optimize patient selection, de-risk clinical development, and enable precision targeting in an underserved and rapidly growing dementia market.